Company press releases

Tid	Selskap	Tittel	Sektor	Kategori
09 Jun 2023 18:00 CEST	IPSEN	Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital	20103015 Pharmaceuticals	Share history
09 Jun 2023 18:00 CEST	IPSEN	Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social	20103015 Pharmaceuticals	Share history
06 Jun 2023 18:00 CEST	IPSEN	IPSEN - Buy-back programme - Art 5 of MAR - Week 22 - 2023	20103015 Pharmaceuticals	Share history
06 Jun 2023 18:00 CEST	IPSEN	IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 22 - 2023	20103015 Pharmaceuticals	Share history
01 Jun 2023 07:00 CEST	IPSEN	Ipsen SA initiates a share buy-back program to cover its free employee share-allocation plan	20103015 Pharmaceuticals	Share history
01 Jun 2023 07:00 CEST	IPSEN	Ipsen SA lance un programme de rachat d’actions pour couvrir son programme d’attribution d’actions gratuites aux salariés	20103015 Pharmaceuticals	Share history
31 May 2023 18:04 CEST	IPSEN	Ipsen S.A. - Combined Shareholders’ Meeting of Ipsen S.A. held on 31 May 2023	20103015 Pharmaceuticals	General meeting / Board Meeting
31 May 2023 18:04 CEST	IPSEN	Ipsen S.A. - Assemblée Générale Mixte des actionnaires d'Ipsen S.A. du 31 mai 2023	20103015 Pharmaceuticals	General meeting / Board Meeting
31 May 2023 07:00 CEST	IPSEN	Ipsen - Description of the regulatory framework of the share repurchase program to be approved at the Combined Shareholders’ Meeting on 31 May 2023	20103015 Pharmaceuticals	Share history
31 May 2023 07:00 CEST	IPSEN	Ipsen - Descriptif du cadre réglementaire du programme de rachat d’actions soumis à l’approbation de l’Assemblée Générale Mixte des actionnaires du 31 mai 2023	20103015 Pharmaceuticals	Share history
26 May 2023 14:20 CEST	IPSEN	Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.	20103015 Pharmaceuticals	Products and services
26 May 2023 14:20 CEST	IPSEN	Ipsen reçoit un avis négatif du Comité des médicaments à usage humain (CHMP) à la suite du réexamen du palovarotène en tant que premier traitement de FOP au sein de l'Union européenne (UE)	20103015 Pharmaceuticals	Products and services
17 May 2023 07:00 CEST	IPSEN	Ipsen to present new Bylvay® (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases	20103015 Pharmaceuticals	Products and services
17 May 2023 07:00 CEST	IPSEN	Ipsen présentera de nouvelles données sur Bylvay® (odévixibat) lors du congrès annuel ESPGHAN, attestant de son engagement à faire progresser le traitement des maladies cholestatiques rares	20103015 Pharmaceuticals	Products and services
10 May 2023 18:00 CEST	IPSEN	Ipsen SA - Monthly information relative to the total number of voting rights and shares composing the share capital - April 2023	20103015 Pharmaceuticals	Share history
10 May 2023 18:00 CEST	IPSEN	Ipsen SA - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social - avril 2023	20103015 Pharmaceuticals	Share history
10 May 2023 14:00 CEST	IPSEN	Ipsen : 2023 CSM - Formalities for making available preparatory documents to the Meeting	20103015 Pharmaceuticals	General meeting / Board Meeting
10 May 2023 14:00 CEST	IPSEN	IPSEN : AGM 2023 - Modalités de mise à disposition des documents préparatoires à l'Assemblée	20103015 Pharmaceuticals	General meeting / Board Meeting

Dato

Kategori

Leverandør